TSOI identifies novel B regulatory cell mechanism for JadiCell universal donor adult stem cell

Getty Images 1184397040

Therapeutic Solutions International (TSOI) filed a patent covering the discovery that JadiCell therapeutic activity in a model of COPD can be transferred to naïve animals by a specialized type of B cell. These findings build upon previous company discoveries that specialized B cells, called “B regulatory cells," correlate with patient response to stem cell therapy. In a series of experiments, TSOI  found that B cell depletion abrogated therapeutic effects of JadiCell in a COPD model, and that transfer of a unique population of B cells to naïve mice was able to induce a protective effect. Furthermore, antibody mediated blockade of the cytokine interleukin-35, was able to block therapeutic activity.

“Today’s findings provide further scientific basis for clinical use of JadiCells in not only acute pulmonary conditions such as COVID-19 ARDS, but also in more chronic degenerative conditions such as COPD,” said James Veltmeyer, MD, TSOI co-inventor and chief medical officer. “By identifying the critical role of interleukin-35 in therapeutic mechanisms, we are one step closer to further increasing the already potent therapeutic effects we observe with these unique cells.”James Veltmeyer, MDJames Veltmeyer, MD

In addition to the patent licensed from JadiCell, LLC (#9,803,176 B2), for respiratory indications, TSOI has several patent applications pending and published covering the whole family of umbilical cord mesenchymal stem cells, to which JadiCell belongs, for treatment of COPD, as well as means of selecting for cells with enhanced activity.


More in COPD
Page 1 of 13
Next Page